Top-line Growth is Likely to Be Driven by Aerovate Therapeutics Inc (AVTE) Stock
Jefferies raised the price target for the Aerovate Therapeutics Inc (NASDAQ:AVTE) stock to “a Buy”. The rating was released on March 25, 2024, according to finviz. The research report from Guggenheim has initiated the stock to Buy, with a price target set at $36. The stock was upgraded by BTIG Research, who disclosed in a […]
